Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants
04 févr. 2020 17h50 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants
31 janv. 2020 08h12 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
30 janv. 2020 16h01 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors
19 déc. 2019 07h00 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting
09 déc. 2019 16h05 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
27 nov. 2019 16h05 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences to Present at Upcoming Investor Conferences
14 nov. 2019 09h44 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
12 nov. 2019 07h00 HE
|
Kezar Life Sciences, Inc.
Step-up dose titration lowered GI side effects while maintaining clinical activityMajority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of...
Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616
08 nov. 2019 16h13 HE
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
06 nov. 2019 16h05 HE
|
Kezar Life Sciences, Inc.
Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GAPhase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are...